Cybin Inc (CYBN) Renews $35M At-The-Market Equity Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St rises as chip stocks' gains offset Middle East jitters
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices slide over 1% as US-Iran conflict clouds Hormuz reopening
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Cybin Announces Renewed At-The-Market Equity Program of up to US$35 Million
August 23, 2023 9:37 PM EDTTORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) (Cybin or the Company), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, announced today that it has renewed its previously established at-the-market equity program (the ATM Program) that allows Cybin to issue and sell up to US$35,000,000 of common shares (Shares) in the capital of the Company from treasury to the public, from time to time, through the Agents (as defined below). All Shares sold under the... More
